WO2008088902A8 - Attenuation of the adaptive immune response - Google Patents

Attenuation of the adaptive immune response Download PDF

Info

Publication number
WO2008088902A8
WO2008088902A8 PCT/US2008/000730 US2008000730W WO2008088902A8 WO 2008088902 A8 WO2008088902 A8 WO 2008088902A8 US 2008000730 W US2008000730 W US 2008000730W WO 2008088902 A8 WO2008088902 A8 WO 2008088902A8
Authority
WO
WIPO (PCT)
Prior art keywords
attenuation
immune response
adaptive immune
host
grafts
Prior art date
Application number
PCT/US2008/000730
Other languages
French (fr)
Other versions
WO2008088902A2 (en
WO2008088902A3 (en
Inventor
Jordan Pober
Deepak Rao
Original Assignee
Univ Yale
Jordan Pober
Deepak Rao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Jordan Pober, Deepak Rao filed Critical Univ Yale
Publication of WO2008088902A2 publication Critical patent/WO2008088902A2/en
Publication of WO2008088902A3 publication Critical patent/WO2008088902A3/en
Publication of WO2008088902A8 publication Critical patent/WO2008088902A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Abstract

The present invention encompasses compositions and methods for attenuating a host's immune system response to a graft, by administering an IL-1 receptor antagonist to a host, thereby improving clinical outcomes for host recipients of grafts.
PCT/US2008/000730 2007-01-17 2008-01-17 Attenuation of the adaptive immune response WO2008088902A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88088507P 2007-01-17 2007-01-17
US60/880,885 2007-01-17

Publications (3)

Publication Number Publication Date
WO2008088902A2 WO2008088902A2 (en) 2008-07-24
WO2008088902A3 WO2008088902A3 (en) 2008-12-04
WO2008088902A8 true WO2008088902A8 (en) 2009-04-09

Family

ID=39636604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/000730 WO2008088902A2 (en) 2007-01-17 2008-01-17 Attenuation of the adaptive immune response

Country Status (1)

Country Link
WO (1) WO2008088902A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016601A1 (en) * 2019-07-25 2021-01-28 Implicit Bioscience Limited Methods and agents for treating acute neuroinflammatory injury

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337072B1 (en) * 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU2003295471B2 (en) * 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25

Also Published As

Publication number Publication date
WO2008088902A2 (en) 2008-07-24
WO2008088902A3 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2010142952A3 (en) Antibodies
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
GEP20125398B (en) Human monoclonal antibodies to activin receptor-like kinase-1
WO2007076070A3 (en) Modulators of muscarinic receptors
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
MX2009004532A (en) Compositions and methods for binding sphingosine-1-phosphate.
EP2402373A3 (en) Anti-EphB4 Antibodies and Methods Using Same
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2007033230A3 (en) Anti-cd3 antibody formulations
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
WO2007127317A3 (en) Humanized c-kit antibody
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2008027812A3 (en) Imidazopyridine and imidazopyrimidine derivatives
SG143136A1 (en) Allophanate-modified stabilizers and the polymer polyols prepared from these stabilizers
WO2008025015A3 (en) Epitope-protein scaffolds and their use
EA201000903A1 (en) ANTITEL TO PCRV-ANTIGEN PSEUDOMONAS AERUGINOSA
WO2007087517A3 (en) Methods for reducing food intake and controlling the weight of animals
WO2007144779A3 (en) Compositions comprising porphyra and methods of making and using thereof
WO2007127506A3 (en) Anti-ephrinb2 antibodies and methods using same
WO2007106915A8 (en) Antibodies to egfl7 and methods for their use
WO2010115555A3 (en) Antibodies against human tweak and uses thereof
WO2007100664A3 (en) Modulators of muscarinic receptors
WO2006058303A3 (en) Modulators of muscarinic receptors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08724656

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08724656

Country of ref document: EP

Kind code of ref document: A2